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INTRODUCTION In November 2015, the Centers for Disease Control and Preven-
tion (CDC) sent a letter to state and territorial epidemiologists, state and territo-
rial public health laboratory directors, and state and territorial health officials. In
this letter, culture-independent diagnostic tests (CIDTs) for detection of enteric
pathogens were characterized as “a serious and current threat to public health
surveillance, particularly for Shiga toxin-producing Escherichia coli (STEC) and Sal-
monella.” The document says CDC and its public health partners are approaching this
issue, in part, by “reviewing regulatory authority in public health agencies to require cul-
ture isolates or specimen submission if CIDTs are used.” Large-scale foodborne outbreaks
are a continuing threat to public health, and tracking these outbreaks is an important
tool in shortening them and developing strategies to prevent them. It is clear that the
use of CIDTs for enteric pathogen detection, including both antigen detection and mul-
tiplex nucleic acid amplification techniques, is becoming more widespread. Furthermore,
some clinical microbiology laboratories will resist the mandate to require submission of
culture isolates, since it will likely not improve patient outcomes but may add significant
costs. Specimen submission would be less expensive and time-consuming for clinical
laboratories; however, this approach would be burdensome for public health laborato-
ries, since those laboratories would need to perform culture isolation prior to typing.
Shari Shea and Kristy Kubota from the Association of Public Health Laboratories, along
with state public health laboratory officials from Colorado, Missouri, Tennessee, and
Utah, will explain the public health laboratories’ perspective on why having access to
isolates of enteric pathogens is essential for public health surveillance, detection, and
tracking of outbreaks and offer potential workable solutions which will allow them to do
this. Marc Couturier of ARUP Laboratories and Melissa Miller of the University of North
Carolina will explain the advantages of CIDTs for enteric pathogens and discuss practical
solutions for clinical microbiology laboratories to address these public health needs.
KEYWORDS Campylobacter jejuni, PulseNet, STEC, Salmonella, Shigella, culture
independent, food-borne pathogens
POINT
Some of the greatest advances in public health—immunizations, clean water, safefood—have their roots in the science of microbiology. Data from clinical microbi-
ology laboratories are continuously collected, analyzed, and interpreted as the back-
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bone of public health surveillance efforts. The success of public health surveillance for
infectious diseases, including enteric diseases, is founded on a strong collaborative
partnership between public health laboratories and clinical laboratories.
A revolution is taking place in the field of enteric microbiology that will test the
strength of these long-standing partnerships. Culture-independent diagnostic tests
(CIDTs) are improving diagnostics in ways that greatly benefit patient care. CIDTs can
test for an array of clinically important infections, including respiratory, bloodstream,
and enteric infections, more quickly and effectively than other methods can. Many of
the benefits and challenges to CIDT implementation were discussed at a CIDT Forum
organized by APHL and CDC in April 2012 (1). APHL lauds the benefits of CIDT
technology while suggesting steps all players can take to avoid unintended negative
consequences (2).
Limited data are available on the current use of CIDT tests in clinical laboratories.
Observations from state public health scientists tell us many clinical laboratories are in
the process of switching to CIDTs for the detection of enteric organisms. In 2015, CDC
found a significant increase in the percentage of enteric infections diagnosed only by
a CIDT compared to the average of such diagnoses between 2012 and 2014 in 10 sites.
Specifically, for 4 pathogens, published data show an increase in positive CIDT reports
in 2015 of 92% for Campylobacter, 284% for Shigella, 247% for Salmonella, and 120% for
Shiga toxin-producing Escherichia coli (STEC) compared with the 2012 to 2014 averages;
the overall increase in CIDT-only reports for these four pathogens was 122% (3).
Accelerated uptake of these tests is expected to continue in the future. APHL encour-
ages our member laboratories to stay in close contact with clinical laboratory partners
to determine planned implementation of any CIDT, particularly for enteric diseases.
Public health approach. To protect, promote, and advance population health in
the absence of traditional culture methods, new technologies must be developed that
do not rely on the recovery of isolates. Until such technologies are developed, vali-
dated, and implemented, public health laboratories face a critical need to preserve
access to clinical sources of enteric microbial isolates. Sending stools or other clinical
material to the public health laboratory for isolation of the detected pathogen is not a
tenable solution for several reasons. By mandate and by practice, public health labo-
ratories are not operated with the intention of handling the work flow associated with
routine culture of large numbers of clinical samples. While any one clinical laboratory
may not encounter a high case count of enteric disease, the total number of enteric
isolates referred to a public health laboratory from across a city, county, or state can
become a large volume of work. For example, the Missouri State Public Health Labo-
ratory receives over 1,000 Salmonella isolates a year, compared to the 300 to 400 stool
samples they process annually for enteric bacteria. If as many as half of those Salmo-
nella isolates began coming in as stool samples from CIDT-positive reactions, the
increase in stool processing would be more than double the current stool enteric
processing for that pathogen. Delaying culture until a specimen can be transported to
the public health laboratory is also problematic, particularly for traditionally labile
organisms, such as Campylobacter and non-O157 STEC.
Public health relies on clinical partners to perform timely isolation from patient
specimens and submit pure cultures, which are then further characterized at the public
health laboratory. With the advent of whole-genome sequencing (WGS) technology
and increased epidemiological capacity to interview ill patients, enteric outbreaks are
being investigated and sources of contamination are being determined quickly based
on a very small number of confirmed related illnesses (Table 1). The loss of even one
patient isolate due to nonviability could be the difference between quickly identifying
a causative food item and letting a contaminated product remain on the grocery store
shelves until more people are made ill.
Public health laboratories have historically used many tools to convey needs and
requirements to our stakeholders. Public health law is one of those tools. State and local
governments use public health law to convey requirements and define roles in a
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concrete and public manner. Such laws provide a level of clarity that enhances
collaborative and long-standing relationships. Given the lack of enforcement provisions
in most public health laws, they should be viewed in the light of effective communi-
cation and standard setting, not as punitive measures. These laws provide clinical
partners who want to do the right thing easy access to the latest rules to help them
proceed accordingly. An analysis of current rules and regulations for all 50 states and
the District of Columbia pertaining to isolate and other clinical material submission was
published by APHL in 2016 (9). This analysis shows that 43 states mandate submission
of isolates or other clinical materials for at least three of the eight pathogens reviewed,
and two-thirds or more of states require submission of five of the eight pathogens
(STEC, Listeria monocytogenes, Salmonella, Shigella, and Vibrio). The majority of states
mandate submission in their administrative rules and regulations; a few states address
submission of isolates or clinical materials in statutes.
PulseNet: effective but in jeopardy. One driving force toward ensuring a safer U.S.
food supply is PulseNet, the National Molecular Subtyping Network for Foodborne
Disease Surveillance (10). PulseNet is a national laboratory network that uses bacterial
DNA fingerprints to connect cases of foodborne illness that may be from a common
food or environmental source. Through PulseNet, public health professionals typically
detect well over one hundred local and multistate foodborne outbreaks each year. In
existence since 1996, PulseNet revolutionized foodborne outbreak investigations by
allowing for faster outbreak detection and effective industry response, thereby pro-
tecting American consumers from contaminated products ranging from produce to
peanut butter to meat and poultry. Since 1996, more than 1 billion pounds of
contaminated food have been recalled—saving lives, time, and money—thanks to
PulseNet (11).
PulseNet is deemed a public health success because it supports public health action
to control outbreaks and elucidate new food hazards. The network has also proven to
be highly cost-effective. A recently published economic evaluation of PulseNet dem-
onstrated the efficiency and value of this network in terms of cost savings (an estimated
$507 million saved every year, an economic benefit about 70 times its cost) and illness
prevention (prevents over 270,000 illnesses a year from Salmonella, STEC, and Listeria)
(12). PulseNet’s success, in large part, can be attributed to front-line clinical laboratory
partners who obtain and submit isolates from ill patients.
Meeting public health needs. The public health community is committed to
meeting our own needs related to the collection of surveillance data as best we can. We
accept that we will bear some costs of maintaining our systems and have shown a
willingness to pay for this. For example, courier service and/or complementary shipping
materials may be available through your state or local public health laboratory. In many
states, such as Colorado, Missouri, and Tennessee, when a clinical partner is unable to
bear the costs of reflex culture, the public health laboratory accepts primary specimens.
The key to finding the best solution in your city/county/state is open communication
with the public health laboratory that serves your jurisdiction.
CDC has supported significant efforts to preserve isolate submission from clinical
laboratories, with an aim to ensure that existing surveillance systems continue to
TABLE 1 Selected food-related recalls by contaminant and case counta
Recalled product Contaminant Case count (reference)
Alfalfa and onion sprouts O157 STEC 7 cases in Minnesota and 2 cases in Wisconsin (4)
1.8 million lbs of ground beef O157 STEC 1 case in Massachusetts, 5 cases in Michigan, 1 case in
Missouri, and 5 cases in Ohio (5)
Several sizes and varieties of flour O121 STEC 42 cases in 21 states, with most states having 1 or 2 cases (6)
Pistachios sold across the U.S. and in
Canada, Mexico, and Peru
Salmonella enterica serovars
Montevideo and Senftenberg
11 cases from 9 states (1 or 2 cases per state) (7)
358 frozen vegetable and fruit products
sold under 42 separate brands
Listeria monocytogenes 1 case in Maryland, 1 case in Washington, and 6 cases in
California (8)
aSelected list of recent food-borne investigations that traced ill patients to a contaminated source more quickly because of available data from 1 or 2 cases in a given
state.
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operate. In the summer of 2015, CDC funded work in 5 jurisdictions to determine
the most efficient methods for isolation of Salmonella and STEC from CIDT-positive
specimens. APHL and CDC will publish cost-effective approaches based on this work
in 2017. Additionally, both CDC and the Food and Drug Administration (FDA) are
investing heavily in the development of WGS as a subtyping method for enteric
pathogens and a wide array of other infectious agents. This transition to WGS will
lead to cost savings by streamlining work flows and eliminating the need for tests
such as traditional serotyping and targeted virulence and antimicrobial resistance
marker detection. The WGS transformation will drive the expansion of both work-
force and information technology capacities, building a more efficient and modern
public health system.
Even with the initial success realized through WGS-based subtyping, this method
relies on isolates and is therefore considered an interim technology for PulseNet. As a
long-term solution, CDC is applying resources to develop enteric surveillance systems
built on metagenomics, amplicon sequencing, and other technologies that do not
require bacterial isolates. This research is in the early stages of development. Today’s
transitional work establishes WGS-derived pathogen databases that are necessary for
the post-isolate era, leading to a public health system that is better prepared to migrate
to culture-independent subtyping methods, such as metagenomics. In the meantime,
isolate recovery efforts remain an important focus.
Meeting clinical needs. We believe clinical laboratories have incentives for per-
forming reflex culture on a majority of positive CIDT specimens. Completing antimi-
crobial susceptibility test requests on Salmonella, Shigella, and Campylobacter isolates
will require culture isolation in the clinical laboratory. The cost of adding culture
isolation of E. coli O157:H7, or all STEC in those laboratories capable of recovering them,
to this list of reflexed pathogens is not a huge burden given the low incidence of this
pathogen. Furthermore, at least in large academic centers, the cost of reflex culture of
positive CIDT specimens is minimal compared to the cost savings of the hundreds of
stool requests tested with a multianalyte panel instead of culture and an ova and
parasite exam. One institution estimated annual costs of $250,000 to $500,000 for
molecular tests, with reimbursement at $2 to $2.5 million (13). For a relatively minimal
expense, shared among clinical and public health partners, together we can achieve
goals that are in everyone’s best interest.
PulseNet is but one surveillance system built to decrease disease burden that relies
on access to clinical isolates. NARMS, the National Antibiotic Resistance Monitoring
System, is the only nationwide surveillance system that monitors antimicrobial resis-
tance in select enteric bacteria from ill persons, retail meat, and food animals. NARMS
is dependent upon bacterial isolates for susceptibility testing and other subtyping
studies, such as WGS. For example, the NARMS team at CDC is currently using WGS,
plasmid transformation studies, and mutational analysis to investigate the recent
emergence of infections caused by a strain of Salmonella enterica serovar Infantis that
expresses a CTX-M-type extended-spectrum beta-lactamase (ESBL). In this strain, a large
multidrug-resistant plasmid confers resistance to ampicillin and clinically important
third-generation cephalosporins, including ceftriaxone (CTX). The plasmid is capable of
spreading antibiotic resistance among bacterial species. Another example of the utility
of isolate-based surveillance is the recent discovery of the MCR-1 gene in human and
pig isolates (14, 15). Since phenotypic and genotypic testing rely on isolation of an
organism and cannot currently be performed on clinical material, obtaining isolates is
an imperative part of the short-term solution to identifying and understanding the
evolution of antimicrobial resistance.
We are pleased that our position aligns with the new “Guideline for Prevention and
Management of Acute Diarrhea” from the American College of Gastroenterology (ACG).
While recognizing that FDA-approved CIDTs can find a causal organism when “tradi-
tional methods” cannot, this ACG guideline supports doing both culture and CIDT and
says that “Before bacterial culture is discarded entirely, it is important to acknowledge
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that multiplex molecular diagnostics do not yield isolates that can be forwarded to
public health laboratories” (16). A New England Journal of Medicine Journal Watch article
summarizes the first ACG recommendation as follows: “In acute diarrhea (duration,
1–14 days), perform stool cultures and new culture-independent molecular assays (if
available) when a patient is at high risk of spreading disease or during outbreaks” (17).
We hope additional medical societies and professional organizations take an interest in
this issue in the future.
Path forward. How can the clinical and public health microbiology community
benefit from CIDT technology without disrupting the extensive and beneficial public
health systems that defend our nation from foodborne illness outbreaks? The primary
recommendation from APHL and ASM is frequent and early communication between
public health laboratories and clinical laboratories when a change in test offerings is
being considered. Some public health laboratories are proactively contacting their
submitting laboratories and are learning that almost 100% of those adopting CIDTs are
willing and able to continue submitting isolates of Salmonella, Shigella, and STEC (S.
Gladbach and R. Atkinson-Dunn, personal communications). Additionally, some clinical
laboratory leaders have conveyed the value that continued submission of isolates to
the public health laboratory for epidemiologic investigations holds for them (18).
Interim guidelines have been released by APHL, CDC, and ASM that can help clinical
laboratories efficiently recover these pathogens while minimizing costs (19). The three
partners will collaborate on final guidelines in 2017, following analysis of newly
available data.
Conclusions. In the near future, molecular microbiologists will be able to determine
a wealth of valuable information about a pathogen from its DNA sequence. Identity,
serotype, virulence factors, antibiotic resistance markers, and molecular subtype will all
be available by reading A’s and T’s and C’s and G’s. Long-term solutions lie in novel
advanced testing methods that provide the above-described information without an
isolate. Developing these solutions will require the efforts of many partners over several
years. In the meantime, we must maintain the effective culture-based surveillance
activities that have served us so well.
What is at stake? The ability to connect ill patients to one another and to
definitively link ill patients to the common source of their foodborne illness, and the
ability to link dispersed cases caused by widely distributed products. Without
isolates, many outbreaks will go undetected, contaminated products will remain on
the market, and important gaps may reopen in our food safety system. In essence,
we will lose the most effective tool we have for improving the safety of the U.S. food
supply.
Shari Shea, Kristy A. Kubota, Hugh Maguire, Stephen Gladbach, Amy Woron
and Robyn Atkinson-Dunn
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COUNTERPOINT
It was not so long ago that the medical and laboratory communities’ view of Shigatoxin-producing E. coli (STEC) was narrowly limited to the O157:H7 serotype. This
perception was multifactorial but was largely due to the limitations of culture methods
that selected only for sorbitol-nonfermenting strains, which were prototypical strains of
O157. As such, traditional culture using sorbitol MacConkey agar dramatically
skewed public health laboratory (PHL) reporting data and clinical perceptions of
STEC, mainly the perception that O157:H7 STEC is the only STEC that matters. It is
only as a result of STEC detection methods that are not primarily dependent on
culture (so-called culture-independent diagnostic tests [CIDTs]) that we subse-
quently discovered the multitude of different serotypes of STEC that can produce
Shiga toxins 1 and/or 2. With the adoption of toxin detection via immunocapture
methods, such as enzyme-linked immunosorbent assay (ELISA) or lateral flow
assays, in many laboratories in the United States, the incidence and detection rates
of non-O157 serotypes of STEC associated with acute diarrhea and hemolytic
uremic syndrome rose prominently (http://www.cdc.gov/ecoli/outbreaks.html). Pre-
sumably, these serotypes were always there, but our test approach was woefully
inadequate. These increased detections were aptly exemplified in the state of Wash-
ington, where the adoption of FDA-approved antigen detection CIDTs led directly to
increased detection of STEC, with significantly more recovery of both O157 and
non-O157 serotypes (1). The PHL that published these data acknowledged that this
increased detection posed a burden of effort on PHLs to subsequently identify the
causative non-O157 types through follow-up cultures using enrichment broths or
primary specimens (1). As we reflect on whether improved detection of outbreak
pathogens can reasonably be considered a “burden,” it would be illogical to argue that
a return to O157 culture only would be prudent simply because it would be less
burdensome. In fact, the opposite is true: with Shiga toxin detection being a CDC-
recommended standard for clinical laboratories, in addition to O157 selective culture
(guidance that was expertly and cooperatively drafted by PHLs and sentinel laboratory
constituents) (2), our ability to detect outbreaks and critical cases of STEC in the sentinel
laboratory has greatly improved clinical care. And with newer CIDTs, we can do even
better!
Although antigen detection CIDTs for STEC have increased detection rates, one
limitation is the requirement of 18 h of preenrichment in liquid broth to maximize
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clinical sensitivity. This was one driving force for retaining O157 selective culture in
standard sentinel laboratory practice, since putative O157 colonies could be rapidly
detected in selective/differential culture in less time than the antigen testing could be
performed. However, in the era of rapid molecular detection methods for Shiga toxin
genes (stx1 and stx2), the turnaround time is dramatically reduced due to removing the
need for broth enrichment. Samples could therefore be routed to a PHL for culture and
identification of the offending STEC strain in potentially less time than is currently
possible using antigen detection CIDTs. Essentially, the downstream recovery process
for STEC is largely unchanged (though possibly improved due to earlier transport to the
PHL), while screening sensitivity is enhanced through superior technology.
If we think more broadly with regard to fastidious enteric pathogens, such as
Campylobacter and Shigella, the discussion becomes slightly more complicated, since
delays in transport and delays in setting up cultures can have marked deleterious
effects on isolate recovery for these pathogens (3, 4). It is important to recognize that
the discrepancies seen between delayed culture of fastidious pathogens and
molecular-CIDT-positive results should not be viewed as false-positive molecular-test
results, as Van Lint and colleagues have demonstrated that Shigella recovery in culture
is impaired after 3 days of refrigerated storage but Salmonella is not significantly
affected. Recent studies have shown increased detection rates for all of the aforemen-
tioned pathogens using molecular CIDTs (4, 5), and it is well known that our current
culture practices, particularly for Campylobacter, are suboptimal and largely unstan-
dardized (3, 6). This then leads to a practical consideration of whether delaying culture
set up is potentially worth the improved detection that can be achieved with molecular
CIDTs, even if all of the specimens cannot be optimally cultured thereafter (a reason-
able concern for Campylobacter and Shigella). One must address the philosophical
debate of whether it is of greater utility to recover isolates for only a fraction of “true
cases” by maintaining insensitive predicate cultures or to detect a greater proportion of
true cases at the risk of sacrificing a subset of samples to suboptimal isolate recovery.
These challenges, in part, sparked a joint effort between key players in PHLs and
sentinel laboratories to draft unified guidelines and recommendations for Campylobac-
ter (in final preparation), akin to what was drafted for STEC. This will likely also force us
to revisit or revise the case definition for more fastidious enteric pathogens like
Campylobacter, to include molecular CIDTs and clear recommendations for isolate/
specimen submission.
Antigen detection CIDTs, in particular for the detection of Campylobacter, have
shown disputed clinical utility due to false-positive results that cannot be confirmed by
culture or molecular assays (5). This could realistically lead to a significant burden to
perform culture for these potentially low-yield samples. However, with highly sensitive
and specific molecular CIDTs in place for routine clinical care and improved detection
rates for samples containing enteric pathogens, the spectrum of samples that would
require culture for outbreak investigation should become higher in yield than with
previous generations of CIDT technology, albeit false-positive results will still occasion-
ally be encountered. The critical question becomes, “Who should assume responsibility
for culturing isolates for outbreak investigation purposes?”
In recent years, this has become a worrisome and polarizing subject in published
works and conference proceedings, unfortunately (and unnecessarily) pitting PHL
mandates against those of sentinel laboratories in a seemingly adversarial tone (7–9).
PHLs have publicly expressed concern for poor financial resources to support these
efforts and generally view CIDTs as a threat to their longstanding procedures for
outbreak investigations despite the opportunities that come with these technologies
(7–9). On the other side of this issue, sentinel laboratories are under greater pressure
from hospital administrators to perform more testing with fewer staff and to reduce
costs. In fact, outcome measures are rapidly becoming a metric for which hospitals hold
physicians and laboratories accountable. If a process incurs expense and provides no
direct clinical benefit to the patient, it essentially should not be performed (e.g.,
culturing a sample that already has a diagnostic CIDT result on a validated assay). Some
Point-Counterpoint Journal of Clinical Microbiology
January 2017 Volume 55 Issue 1 jcm.asm.org 16
laboratories that have adopted expensive CIDT molecular assays were required to
outright cease stool culture to maintain cost-effectiveness. If culturing for isolates is
simply a service to support public health outbreak investigations and plays no direct
role in clinical care to the index patient, then this extra cost is difficult to justify in the
sentinel laboratory. Another way to look at this would be to ask whether a private
hospital laboratory or a private payer should be incurring expenses that are not of
clinical necessity. When considered in this context, the discourse rapidly evolves away
from practical laboratory discussions and toward government policy/potential legal
recourse if culture enforcement is sought through forced legislation rather than col-
laboration and compromise.
How can this potential quagmire be avoided? It is paramount that we engage this
in the same way we have for STEC and Campylobacter: collaboratively and through
frank, open, constructive discourse between key stakeholders in PHLs and sentinel
laboratories. Interim guidelines have already been collaboratively drafted between the
American Society for Microbiology and the Association of Public Health Laboratories
(10) and serve as a prime example of the advances we can achieve by working
collaboratively to address these challenges. Lobbying for government intervention to
force the hand of sentinel laboratories to perform reflex cultures is unconstructive and
divisive. Likewise, outright refusal by sentinel laboratories to consider any compromise
that includes selective culturing of stool samples that test positive by CIDTs will not
move the discussion toward a reasonable solution either. PHLs and sentinel laboratories
are a team (despite sometimes skewed perceptions to the contrary), and it is imperative
that we continue to work together to best serve the individual patient, as well as the
community at large.
How can we achieve this? Sentinel laboratories and their partners in PHLs must
have discussions IN ADVANCE of implementing a CIDT to find a practical solution. Some
discussion points to address include the following.
● Does the CIDT allow for subsequent culture of samples (i.e., preserved stools are
collected)?
● Does the sentinel laboratory intend to maintain any stool culture capabilities? If
not, would they consider directed culture on a limited basis for samples that test
positive by CIDTs?
● Can PHLs solely assume the responsibility for culturing all samples with positive
CIDTs?
● If the PHL cannot handle the burden of culturing all positives, as has been stated
in several texts, can sentinel laboratories and PHLs establish a system for remu-
neration (perhaps via appropriated government funding) to maintain selective
media as necessary for directed cultures in the sentinel laboratory? This could
potentially be accomplished through the use of regional laboratory services.
This final point is likely the most practical option and should be explored. Directed
cultures would involve only setting up a selective media for the organism(s) identified
by the CIDT and submitting the subsequent growth to the PHL for further character-
ization. It would be illogical to perform an entire conventional stool culture interroga-
tion when the laboratory knows what the offending pathogen is that needs to be
targeted (this would also reduce the associated expenses). In the case of STEC, sentinel
laboratories could continue to simply submit preserved stools or an enrichment broth.
For Salmonella/Shigella, an appropriate medium (e.g., Hektoen enteric agar) could be
set up for culture, and likewise for Campylobacter (e.g., Campy CVA). This could be a
realistic solution if we cooperatively utilize our combined strengths and interests to
jointly lobby for government resources to fund these important efforts. This could be
pursued on a state or federal level as deemed appropriate, with support from profes-
sional societies. Along these same lines, the public health sector must pursue new
technologies for culture-independent strain typing directly from stool samples in order
to parallel the enhanced detection realized by molecular CIDTs. This cannot be
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achieved without adequate funding from appropriate government agencies and
should be an effort supported at the federal, state, and local levels.
These technologies should not be feared but, rather, should be viewed as an
opportunity. There are multiple studies that have highlighted the sensitivity increase
seen when molecular CIDTs are tested against antigen CIDTs, and this is likely the future
method of choice for most sentinel laboratories, as part of “syndromic panels” (11–14).
In fact, early adopters of these technologies have experienced more frequent identifi-
cation of reportable gastrointestinal pathogens than with traditional methods, which
carries the potential to identify more outbreaks, identify outbreaks earlier, and aid in
reducing additional or secondary transmission events (15). Norovirus is one such
example of the positive impact to public health reporting and outbreak detection that
can be realized through the use of syndromic panel testing. This should be viewed as
an opportunity to increase diagnosis and subsequent isolate recovery in the case of
bacterial pathogens, rather than a threat to public health surveillance.
Are CIDTs a threat to public health surveillance? They certainly could be IF we
collectively fail to collaboratively find a solution for this challenge that meets the needs
of the patient and the greater community. We’ve been successful before, we’ve jointly
drafted interim guidance; so what is stopping us from executing this further?
Marc Roger Couturier and Melissa B. Miller
ACKNOWLEDGMENTS
M.R.C. has received research support from BioGX (Birmingham, Alabama). M.B.M. has
received research funding from Luminex Molecular Diagnostics and Cepheid.
REFERENCES
1. Stigi KA, Macdonald JK, Tellez-Marfin AA, Lofy KH. 2012. Laboratory
practices and incidence of non-O157 Shiga toxin-producing Escherichia
coli infections. Emerg Infect Dis 18:477–479. https://doi.org/10.3201/
eid1803.111358.
2. Gould LH, Bopp C, Strockbine N, Atkinson R, Baselski V, Body B, Carey R,
Crandall C, Hurd S, Kaplan R, Neill M, Shea S, Somsel P, Tobin-D’Angelo
M, Griffin PM, Gerner-Smidt P, Centers for Disease Control and Preven-
tion. 2009. Recommendations for diagnosis of Shiga toxin-producing
Escherichia coli infections by clinical laboratories. MMWR Recomm Rep
58(RR-12):1–14. https://www.cdc.gov/mmwr/preview/mmwrhtml/
rr5812a1.htm.
3. Hurd S, Patrick M, Hatch J, Clogher P, Wymore K, Cronquist AB, Segler S,
Robinson T, Hanna S, Smith G, Fitzgerald C. 2012. Clinical laboratory
practices for the isolation and identification of Campylobacter in Food-
borne Diseases Active Surveillance Network (FoodNet) sites: baseline
information for understanding changes in surveillance data. Clin Infect
Dis 54(Suppl 5):S440–S445. https://doi.org/10.1093/cid/cis245.
4. Van Lint P, De Witte E, Ursi JP, Van Herendael B, Van Schaeren J. 2016.
A screening algorithm for diagnosing bacterial gastroenteritis by real-
time PCR in combination with guided culture. Diagn Microbiol Infect Dis
85:255–259. https://doi.org/10.1016/j.diagmicrobio.2016.03.017.
5. Fitzgerald C, Patrick M, Gonzalez A, Akin J, Polage CR, Wymore K,
Gillim-Ross L, Xavier K, Sadlowski J, Monahan J, Hurd S, Dahlberg S,
Jerris R, Watson R, Santovenia M, Mitchell D, Harrison C, Tobin-
D’Angelo M, DeMartino M, Pentella M, Razeq J, Leonard C, Jung C,
Achong-Bowe R, Evans Y, Jain D, Juni B, Leano F, Robinson T, Smith
K, Gittelman RM, Garrigan C, Nachamkin I. 2016. Multicenter evalua-
tion of clinical diagnostic methods for detection and isolation of
Campylobacter spp. from stool. J Clin Microbiol 54:1209 –1215.
https://doi.org/10.1128/JCM.01925-15.
6. M’Ikanatha NM, Dettinger LA, Perry A, Rogers P, Reynolds SM, Nacham-
kin I. 2012. Culturing stool specimens for Campylobacter spp., Pennsyl-
vania, USA. Emerg Infect Dis 18:484–487. https://doi.org/10.3201/
eid1803.111266.
7. Huang JY, Henao OL, Griffin PM, Vugia DJ, Cronquist AB, Hurd S,
Tobin-D’Angelo M, Ryan P, Smith K, Lathrop S, Zansky S, Cieslak PR,
Dunn J, Holt KG, Wolpert BJ, Patrick ME. 2016. Infection with patho-
gens transmitted commonly through food and the effect of increas-
ing use of culture-independent diagnostic tests on surveillance—
Foodborne Diseases Active Surveillance Network, 10 U.S. sites, 2012-
2015. MMWR Morb Mortal Wkly Rep 65:368–371. https://doi.org/
10.15585/mmwr.mm6514a2.
8. Jones TF, Gerner-Smidt P. 2012. Nonculture diagnostic tests for enteric
diseases. Emerg Infect Dis 18:513–514. https://doi.org/10.3201/
eid1803.111914.
9. Atkinson R, Maguire H, Gerner-Smidt P. 2013. A challenge and an
opportunity to improve patient management and public health sur-
veillance for food-borne infections through culture-independent di-
agnostics. J Clin Microbiol 51:2479–2482. https://doi.org/10.1128/
JCM.00253-13.
10. Association of Public Health Laboratories. 2016. Submission of enteric
pathogens from positive culture-independent diagnostic test specimens
to public health: interim guidelines. https://www.aphl.org/aboutAPHL/
publications/Documents/FS-Enteric_Pathogens_Guidelines_0216.pdf.
11. Chui L, Lee MC, Allen R, Bryks A, Haines L, Boras V. 2013. Comparison
between ImmunoCard STAT!(®) and real-time PCR as screening tools for
both O157:H7 and non-O157 Shiga toxin-producing Escherichia coli in
Southern Alberta, Canada. Diagn Microbiol Infect Dis 77:8–13. https://
doi.org/10.1016/j.diagmicrobio.2013.05.015.
12. Chui L, Lee MC, Malejczyk K, Lim L, Fok D, Kwong P. 2011. Prevalence of
Shiga toxin-producing Escherichia coli as detected by enzyme-linked
immunoassays and real-time PCR during the summer months in north-
ern Alberta, Canada. J Clin Microbiol 49:4307–4310. https://doi.org/
10.1128/JCM.05211-11.
13. Qin X, Klein EJ, Galanakis E, Thomas AA, Stapp JR, Rich S, Buccat AM, Tarr
PI. 2015. Real-time PCR assay for detection and differentiation of Shiga
toxin-producing Escherichia coli from clinical samples. J Clin Microbiol
53:2148–2153. https://doi.org/10.1128/JCM.00115-15.
14. Vallieres E, Saint-Jean M, Rallu F. 2013. Comparison of three different
methods for detection of Shiga toxin-producing Escherichia coli in a
tertiary pediatric care center. J Clin Microbiol 51:481–486. https://
doi.org/10.1128/JCM.02219-12.
15. Binnicker MJ. 2015. Multiplex molecular panels for diagnosis of gastro-
intestinal infection: performance, result interpretation, and cost-
effectiveness. J Clin Microbiol 53:3723–3728. https://doi.org/10.1128/
JCM.02103-15.
Point-Counterpoint Journal of Clinical Microbiology
January 2017 Volume 55 Issue 1 jcm.asm.org 18
SUMMARY
Points of agreement
1. PulseNet has played an irreplaceable role in the detection and control of numer-
ous foodborne outbreak in the United States. The current technology available to
PulseNet requires bacterial isolates for analysis.
2. Culture-independent diagnostic tests (CIDT) enhance the detection of the major
foodborne pathogens under surveillance by PulseNet: Campylobacter, Salmo-
nella, Shigella, and Shiga toxin-producing Escherichia coli.
3. Having to recover organisms that have already been detected by CIDT will add
unreimbursed expense for laboratories, a cost that many health care systems will
not want to bear. Solutions to this problem will require agreement between
diagnostic and public health laboratories.
4. Molecular methods of typing foodborne pathogens directly from clinical speci-
mens are on the horizon, but this is clearly a long-term solution. A short-term
solution is essential, since the bacterial isolates are essential for public health
surveillance and diagnostic laboratories are becoming increasingly dependent on
CIDTs.
Points requiring further consideration
1. Is it reasonable to expect public health laboratories to perform culture isolation
from CIDT-positive stool specimens when they are already facing staffing and
financial challenges?
2. Would rules or statutes which require diagnostic laboratories to subculture
CIDT-positive specimens be the most cost-efficient means of providing isolates to
public health laboratories?
3. What role do government agencies have in mandating how these organisms are
recovered? For example, can a Current Procedural Terminology (CPT) code be
established specifically for subculture of CIDT-positive specimens so that some
level of reimbursement can be obtained? Alternatively, does the public value the
safety of the food supply sufficiently to agree to a tax on food purchases to
support public health laboratories’ surveillance of foodborne outbreaks?
Peter H. Gilligan, Point-Counterpoint Editor, Journal of Clinical Microbiology
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